Bioatla, Inc.
Clinical trials sponsored by Bioatla, Inc., explained in plain language.
A clinical-stage biotech developing conditionally active biologics for cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug shows promise for tough head and neck cancers
Disease control CompletedThis study tested an experimental drug called ozuriftamab vedotin in 42 people with head and neck cancer that returned or spread. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received the drug alone or with other treatments, and …
Phase: PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug combo shows promise for tough lung cancers
Disease control CompletedThis phase 2 trial tested a new drug called BA3011, alone or with an immunotherapy, in 85 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if the drug could shrink tumors and how safe it was. The study is now complet…
Phase: PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental drug combo targets Hard-to-Treat sarcomas
Disease control CompletedThis study tested a new drug called mecbotamab vedotin, alone or with the immunotherapy nivolumab, in 245 adults and teens aged 12+ with advanced solid tumors, including sarcomas. The goal was to check safety and see if the drug shrinks tumors. The trial is now complete, and resu…
Phase: PHASE1, PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC